Why it matters: The cash infusion signals balance-sheet strain at Valentino and prolongs Kering’s turnaround timeline.
Impact: Short-term liquidity improves, but rising leverage and delayed full acquisition could weigh on valuation and near-term earnings.
What to follow: Monitor Valentino’s sales and EBITDA trajectory in 2025, any further equity injections or covenant resets, and updates to Kering’s acquisition timing.